Home / Market News / $BIAF
benzinga Corporate Catalyst Impact 55/100 ● positive

bioAffinity Technologies, AvMEDICAL Deliver First Joint Exhibition Of CyPath Lung

Sep 30, 2026, 12:05 PM UTC · Primary ticker $BIAF

bioAffinity Technologies and its partner AvMEDICAL showcased their CyPath Lung diagnostic test at a major veterans' healthcare conference. This event marks the first joint exhibition under their new distribution agreement, aiming to expand the test's reach within the federal healthcare system, particularly for veterans.

bioAffinity Technologies (BIAF) and its federal healthcare distribution partner AvMEDICAL held their first joint exhibition of CyPath Lung at the National Association of Veterans’ Research and Education Foundations (NAVREF) Annual Conference. This event is significant because it represents the initial operational step in their recently announced distribution agreement, specifically targeting the large and critical veteran healthcare market. For BIAF, this increases the visibility and potential adoption of its lung cancer test among a key demographic and within a specific healthcare system. While not a direct revenue announcement, it's a positive step towards market penetration and could lead to future sales, offering a moderate long-term opportunity for the stock as it expands its commercial footprint. The short-term impact is likely neutral to slightly positive as it confirms execution on a previously announced strategy.

$BIAF positive Increased visibility and market penetration for key product
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.